Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT03497429 Completed - Clinical trials for Advanced Solid Tumors

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

Start date: April 5, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.

NCT ID: NCT03490669 Completed - Ovarian Cancer Clinical Trials

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors. In part 1, multiple dose levels of MSC-1 in patients with advanced solid tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in Part 2.

NCT ID: NCT03472352 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors

Start date: April 2018
Phase: Phase 1
Study type: Interventional

This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.

NCT ID: NCT03463473 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study of MSB2311 in Advanced Solid Tumors

Start date: April 12, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.

NCT ID: NCT03461952 Terminated - Clinical trials for Advanced Solid Tumors

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

NIMBLe
Start date: March 11, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.

NCT ID: NCT03440450 Recruiting - Clinical trials for Advanced Solid Tumors

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors.

NCT ID: NCT03439761 Recruiting - Clinical trials for Advanced Solid Tumors

An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Start date: March 7, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Use PT-112 alone for Phase I dose escalation stage: advanced solid tumors, Phase I dose confirmation stage: advanced solid tumors. Phase II hepatocellular carcinoma (HCC). To evaluate the safety and tolerability of PT-112 injection from 250mg/m2 dose level with 3+3 dose escalation design, find Maximum tolerated dose (MTD), Recommended Phase II Dose(RP2D) and evaluate the Pharmacokinetic (PK) profile of PT-112 through Phase I dose escalation stage. Phase I dose confirmation stage: evaluate the safety and tolerability of PT-112 with RP2D, evaluate the anti-tumor effect of PT-112 at RP2D. Phase II stage: evaluate the anti-tumor effect of PT-112 at RP2D in advanced HCC

NCT ID: NCT03435250 Terminated - Lymphoma Clinical Trials

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Start date: March 4, 2018
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.

NCT ID: NCT03429218 Completed - Clinical trials for Advanced Solid Tumors

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

Start date: July 10, 2018
Phase: Phase 1
Study type: Interventional

TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active serine/threonine receptor kinase due to activating mutations or upregulated upstream signaling pathways. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-0184 administered once weekly for 4 weeks in patients with advanced solid tumors.

NCT ID: NCT03415659 Recruiting - Clinical trials for Advanced Solid Tumors

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Start date: March 5, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to investigate the safety, tolerability, and efficacy of HWH340. In addition, the pharmacokinetic characteristics will also be investigated. Three parts are included in this study.